Abstract Details
Michelle L. Mellion, MD
PRESENTER |
Dr. Mellion has received personal compensation for serving as an employee of PepGen. Dr. Mellion has stock in PepGen. |
No disclosure on file | |
No disclosure on file | |
No disclosure on file | |
No disclosure on file | |
No disclosure on file | |
No disclosure on file | |
No disclosure on file | |
No disclosure on file | |
No disclosure on file | |
No disclosure on file | |
No disclosure on file | |
No disclosure on file | |
No disclosure on file | |
Alrabi Tawil, MD, FAAN (University of Rochester Medical Center) | Dr. Tawil has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Kate Therapeutics. Dr. Tawil has received personal compensation in the range of $500-$4,999 for serving as a Consultant for meRicule. The institution of Dr. Tawil has received research support from Friends of FSH Research. The institution of Dr. Tawil has received research support from FSH Society. The institution of Dr. Tawil has received research support from NIH. The institution of Dr. Tawil has received research support from Fulcrum. Dr. Tawil has received intellectual property interests from a discovery or technology relating to health care. |
No disclosure on file | |
Diego Cadavid, MD, FAAN (Verge Genomics) | Dr. Cadavid has received personal compensation for serving as an employee of Verge Genomics. Dr. Cadavid has received personal compensation for serving as an employee of X4 Pharmaceuticals. Dr. Cadavid has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pheno Therapeutics. Dr. Cadavid has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novo Nordisk. Dr. Cadavid has stock in Verge Genomics. |
No disclosure on file |